Dermatológia pre prax 3/2011

Fluorinated and non-fluorinated topical corticosteroids in dermatological practice: the unique position of mometasone furoate

In 1952, Sulzberger and Witten first reported the successful use of topical hydrocortisone acetate in the treatment of skin diseases. For more than half a century, local corticosteroids meant for millions of patients a significant improvement of dermatological diseases and thus quality of their life (13). The main problem with topical corticosteroids is that the same mechanism of action responsible for their therapeutic effects (anti-inflammatory, antiproliferative activity) may also cause undesirable side expressions. Handling the chemical structure of the steroid nucleus, in particular halogenation and esterification significantly increased therapeutic effect while limiting the time of application, location and age of the target group. Mometasone furoate as the only potent non-fluorinated topical corticosteroids has in addition to the minimum of side effects and a once daily application also benefit of use in pediatric practice.

Keywords: topical corticosteroids, halogenition, safety of treatment, side effects, non-fluorinated corticosteroids, mometasone furoate